GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » 10-Year RORE %

Baxter International (Baxter International) 10-Year RORE % : 4.08% (As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Baxter International 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Baxter International's 10-Year RORE % for the quarter that ended in Dec. 2023 was 4.08%.

The industry rank for Baxter International's 10-Year RORE % or its related term are showing as below:

BAX's 10-Year RORE % is ranked better than
55.7% of 395 companies
in the Medical Devices & Instruments industry
Industry Median: 2.45 vs BAX: 4.08

Baxter International 10-Year RORE % Historical Data

The historical data trend for Baxter International's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International 10-Year RORE % Chart

Baxter International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.99 -7.37 -7.35 -61.24 4.08

Baxter International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.24 -65.21 -77.01 10.51 4.08

Competitive Comparison of Baxter International's 10-Year RORE %

For the Medical Instruments & Supplies subindustry, Baxter International's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Baxter International's 10-Year RORE % falls into.



Baxter International 10-Year RORE % Calculation

Baxter International's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 5.22-4.56 )/( 26.542-10.365 )
=0.66/16.177
=4.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Baxter International  (NYSE:BAX) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Baxter International 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Baxter International's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxter International (Baxter International) Business Description

Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Executives
Joel T. Grade officer: EVP, Chief Financial Officer SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth officer: EVP, Group Pres, Kidney Care 1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul officer: EVP, Group Pres, Healthcare ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig officer: EVP, Group President, Pharm ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight officer: EVP, Group Pres, Medical ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler officer: SVP, Chief Quality Officer ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason officer: CVP, Human Resources ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn officer: SVP, President, APAC ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver director
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith director TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403

Baxter International (Baxter International) Headlines